目的分析云克联合甲氨蝶呤、来氟米特治疗类风湿关节炎的疗效及安全性。方法将66例类风湿关节炎患者随机分为两组,观察组33例采用静脉滴注云克联合口服甲氨蝶呤、来氟米特治疗,对照组33例单纯口服甲氨蝶呤、来氟米特治疗。观察治疗后12周的关节症状、实验室指标变化,评价其疗效及不良反应。结果治疗12周后,观察组关节症状、实验室指标与治疗前相比均显著改善,差异有统计学意义(P<0.05),而对照组仅个别实验室指标有所改善,差异有统计学意义(P<0.05);与对照组比较,观察组治疗后,相关指标均明显优于对照组,差异有统计学意义(P<0.05)。两组均未出现严重不良反应,不良反应发生率,差异无统计学意义(P>0.05)。结论云克联合甲氨蝶呤、来氟米特治疗类风湿关节炎疗效显著、安全性好。 Objective To analyze the efficacy and safety of Yunke combined with methotrexate and leflunomide in the treatment of rheumatoid arthritis. Methods Sixty-six patients with rheumatoid arthritis were randomly divided into two groups. 33 cases in the observation group received intravenous drip of vancomycin combined with oral methotrexate and leflunomide, while 33 in the control group received oral methotrexate alone Filtration treatment. Observed 12 weeks after treatment of joint symptoms, laboratory changes in indicators to evaluate the efficacy and adverse reactions. Results After 12 weeks of treatment, the joint symptoms and laboratory indexes in the observation group were significantly improved compared with those before treatment (P <0.05), while those in the control group were only improved in some laboratories with statistically significant differences (P <0.05). Compared with the control group, the relevant indexes in the observation group were significantly better than those in the control group, the difference was statistically significant (P <0.05). No serious adverse reactions were found in both groups, the incidence of adverse reactions, no significant difference (P> 0.05). Conclusion Yunke combined methotrexate, leflunomide treatment of rheumatoid arthritis significant effect, good safety.